Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic atopic dermatitis (AD) according to American Academy of Dermatology Consensus Criteria that has been present for ≥1 year before screening.~* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.~* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit.~* ≥10% Body Surface Area (BSA) of AD involvement at the baseline visit.~* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.~* Have not received any tetanus-containing vaccine within approximately 5 years of baseline.~* Have never received a meningococcal conjugate vaccine or have received not more than 1 prior MCV dose at least 4 years prior to baseline, of a vaccine containing 1 or more meningococcal serogroups (serogroups A, C, W, Y).~* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~  * a. Female participants of childbearing potential: must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of study drug. Women of non-childbearing potential (non-WOCBP) may participate without any contraception requirements.~ * b. Male participants are not required to use any contraception except in compliance with specific local government study requirements.~Exclusion Criteria:~* Recurring herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis~* Evidence of active or chronic hepatitis~* History of human immunodeficiency virus (HIV) infection or positive HIV serology.~* Presence of skin comorbidities that may interfere with study assessments.~* History of malignancy, including mycosis fungoides, within 5 years before screening, except completely treated in situ carcinoma of the cervix or completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma.~* Have a prior history of Guillain-Barre syndrome.~* Allergic to latex.~* History of past vaccination allergy or Arthus-type hypersensitivity.~* Have an uncontrolled seizure disorder.~* Have known hypogammaglobulinemia or a screening serum immunoglobulin G (IgG) or immunoglobulin A (IgA) concentration less than the lower limit of the reporting laboratory's reference range.~* Treated with topical corticosteroids (TCS), calcineurin inhibitors, or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit.~* Treated with the following prior to baseline visit:~  * a. An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer~ * b. B Cell-depleting biologics, including rituximab, within 6 months~ * c. Other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer~* Received a Bacillus Calmette-Guerin (BCG) vaccination or treatment within 12 months of screening, or treated with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.~* A contraindication to the Tdap vaccine or mean corpuscular volume (MCV).~* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lebrikizumab (Type: EXPERIMENTAL): Participants received a loading dose of 500 milligram (mg) lebrikizumab injection administered subcutaneously (SC) at baseline and week 2, and 250 mg once every two weeks (Q2W) from week 4 to 14.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo SC injection Q2W from baseline to week 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).